SCHEMBL148383

SCHEMBL148383

[CH2]C#CC(C)CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120964 0.84
SCHEMBL2118765 0.82 OPRM1 (0.42)
SCHEMBL29588132 0.82 TSHR (0.38)
SCHEMBL8960477 0.76 TSHR (0.31)
SCHEMBL30368458 0.74
SCHEMBL5561973 0.74
SCHEMBL2121226 0.74
SCHEMBL22418876 0.72
SCHEMBL28182600 0.72 DNM1 (0.38)
SCHEMBL17219861 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP claimed
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed
EP-4392420-A1 HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME BIOFRONT LTD (KY) 2024-07-03 EP disclosed
US-20240208909-A1 SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2024-06-27 US disclosed
EP-3835298-B1 NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC (US) 2024-06-26 EP disclosed
CN-114126606-B Method for dispersing a biofilm comprising gram-negative bacteria Q生物股份有限公司 2024-06-21 CN disclosed
US-12011445-B2 Prevention of pancreatic cell degeneration MELIOR PHARMACEUTICALS I, INC. (US) 2024-06-18 US disclosed
WO-2024118966-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. (US) 2024-06-06 WO disclosed
WO-2024118960-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. (US) 2024-06-06 WO disclosed
WO-2002030884-A2 SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
WO-2002030863-A2 ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
WO-2002030860-A2 KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
US-20020045639-A1 COMBINATION OF HUPERZINE AND NICOTINIC COMPOUNDS AS A NEUROPROTECTIVE AGENT US ARMY, SECRETARY OF THE ARMY 2002-04-18 US disclosed
WO-2002030882-A2 SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
WO-2002011712-A2 COMBINATION OF HUPERZINE AND NICOTINIC COMPOUNDS AS A NEUROPROTECTIVE AGENT GEORGETOWN UNIVERSITY (US) 2002-02-14 WO disclosed
WO-2000059855-A1 ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF ESPERION THERAPEUTICS, INC. (US) 2000-10-12 WO disclosed
US-5965611-A TREATING CHRONIC PERIPHERAL ARTERIAL OCCLUSION BY ADMINISTERING EMULSION COMPRISING ISOCARBACYCLIN, VEGETABLE OIL, PHOSPHOLIPID, AND WATER TEIGIN LIMITED (JP) 1999-10-12 US disclosed
EP-0761225-A1 PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL CIRCULATION DISORDER TEIJIN LIMITED (JP) 1997-03-12 EP disclosed
CN-1102038-A External skin therapeutic agent composition containing prostacyclin as active ingredient TEIJIN LTD (JP) 1995-04-26 CN disclosed